Home>
US Stocks>
Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc share price today

(LCTX)

Lineage Cell Therapeutics Inc share price is $0.57 & ₹48.25 as on 6 Dec 2024, 2.30 'hrs' IST

$0.57

▲

0.05

(9.4%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Lineage Cell Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Lineage Cell Therapeutics Inc from India. Also see the sentimental analysis on Indian investors investing in Lineage Cell Therapeutics Inc. Get details on the Indian mutual funds that are investing in Lineage Cell Therapeutics Inc. Get Analyst recommendations and forecasts along with all the Lineage Cell Therapeutics Inc's financials.

Lineage Cell Therapeutics Inc share price movements

$0.52
$0.59
$0.57
8.77%
Downside
Day's Volatility :12.16%
Upside
3.72%
$0.50
$1.61
$0.57
12.28%
Downside
52 Weeks Volatility :68.94%
Upside
64.6%

Lineage Cell Therapeutics Inc Returns

Period	Lineage Cell Therapeutics Inc	Index (Russel 2000)
3 Months	-31.67%	0.0%
6 Months	-41.11%	0.0%
1 Year	-46.62%	0.0%
3 Years	-75.17%	-19.7%

Lineage Cell Therapeutics Inc Key Statistics

in dollars & INR

Previous Close	$0.5221
Open	$0.5236
Today's High	$0.592
Today's Low	$0.52
Market Capitalization	$125.9M
Today's Volume	$1.3M
52 Week High	$1.61
52 Week Low	$0.5
Revenue TTM	$6.2M
EBITDA	$-21.4M
Earnings Per Share (EPS)	$-0.1
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-35.04%

How to invest in Lineage Cell Therapeutics Inc from India?

It is very easy for Indian residents to invest directly in Lineage Cell Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Lineage Cell Therapeutics Inc stock in both rupees (INR) and dollars (USD). Search for Lineage Cell Therapeutics Inc or LCTX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Lineage Cell Therapeutics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Lineage Cell Therapeutics Inc shares which would translate to 1.485 fractional shares of Lineage Cell Therapeutics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Lineage Cell Therapeutics Inc

220%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Lineage Cell Therapeutics Inc on INDmoney from India has grown in the last 30 days as on Dec 6, 2024. 220% more investors are searching Lineage Cell Therapeutics Inc in the last 30 days versus the previous period.

Analyst Recommendation on Lineage Cell Therapeutics Inc

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Lineage Cell Therapeutics Inc(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Lineage Cell Therapeutics Inc

What analysts predicted

Upside of 747.95%

Current:

$0.57

Target:

$4.83

Insights on Lineage Cell Therapeutics Inc

Increasing Revenue
Revenue is up for the last 2 quarters, 1.40M → 3.77M (in $), with an average increase of 62.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -6.54M → -3.03M (in $), with an average increase of 51.7% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 43.9% return, outperforming this stock by 87.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 115.4%

Lineage Cell Therapeutics Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.4M	↓ 20.98%
Net Income	$-46.0M	↑ 130.23%
Net Profit Margin	-3.2K%	↓ 2133.15%

	FY19	Y/Y Change
Revenue	$1.5M	↑ 4.38%
Net Income	$-11.8M	↓ 74.28%
Net Profit Margin	-800.2%	↑ 2447.68%

	FY20	Y/Y Change
Revenue	$773.0K	↓ 47.7%
Net Income	$-20.7M	↑ 74.9%
Net Profit Margin	-2.7K%	↓ 1875.74%

	FY21	Y/Y Change
Revenue	$3.9M	↑ 404.01%
Net Income	$-38.6M	↑ 86.43%
Net Profit Margin	-989.84%	↑ 1686.1%

	FY22	Y/Y Change
Revenue	$14.7M	↑ 277.39%
Net Income	$-26.4M	↓ 31.66%
Net Profit Margin	-179.24%	↑ 810.6%

	FY23	Y/Y Change
Revenue	$8.9M	↓ 39.16%
Net Income	$-21.5M	↓ 18.47%
Net Profit Margin	-240.2%	↓ 60.96%

	Q2 FY23	Q/Q Change
Revenue	$3.2M	↑ 35.16%
Net Income	$-5.2M	↑ 18.73%
Net Profit Margin	-162.14%	↑ 22.44%

	Q3 FY23	Q/Q Change
Revenue	$1.2M	↓ 61.36%
Net Income	$-7.1M	↑ 35.97%
Net Profit Margin	-570.63%	↓ 408.49%

	Q4 FY23	Q/Q Change
Revenue	$2.1M	↑ 67.58%
Net Income	$-4.8M	↓ 32.84%
Net Profit Margin	-228.69%	↑ 341.94%

	Q1 FY24	Q/Q Change
Revenue	$1.4M	↓ 30.84%
Net Income	$-6.5M	↑ 37.01%
Net Profit Margin	-453.05%	↓ 224.36%

	Q2 FY24	Q/Q Change
Revenue	$1.4M	↓ 2.49%
Net Income	$-5.8M	↓ 11.95%
Net Profit Margin	-409.09%	↑ 43.96%

	Q3 FY24	Q/Q Change
Revenue	$3.8M	↑ 168.39%
Net Income	$-3.0M	↓ 47.33%
Net Profit Margin	-80.29%	↑ 328.8%

	FY18	Y/Y Change
Total Assets	$101.7M	↓ 41.32%
Total Liabilities	$9.4M	↑ 4.86%

	FY19	Y/Y Change
Total Assets	$125.5M	↑ 23.43%
Total Liabilities	$14.2M	↑ 51.17%

	FY20	Y/Y Change
Total Assets	$107.9M	↓ 13.97%
Total Liabilities	$12.8M	↓ 9.9%

	FY21	Y/Y Change
Total Assets	$174.5M	↑ 61.69%
Total Liabilities	$83.6M	↑ 552.37%

	FY22	Y/Y Change
Total Assets	$123.7M	↓ 29.15%
Total Liabilities	$51.7M	↓ 38.16%

	FY23	Y/Y Change
Total Assets	$101.0M	↓ 18.31%
Total Liabilities	$39.0M	↓ 24.61%

	Q2 FY23	Q/Q Change
Total Assets	$111.7M	↓ 1.34%
Total Liabilities	$40.4M	↓ 8.51%

	Q3 FY23	Q/Q Change
Total Assets	$106.2M	↓ 4.96%
Total Liabilities	$39.5M	↓ 2.32%

	Q4 FY23	Q/Q Change
Total Assets	$101.0M	↓ 4.84%
Total Liabilities	$39.0M	↓ 1.26%

	Q1 FY24	Q/Q Change
Total Assets	$108.5M	↑ 7.39%
Total Liabilities	$37.5M	↓ 3.85%

	Q2 FY24	Q/Q Change
Total Assets	$102.8M	↓ 5.24%
Total Liabilities	$35.9M	↓ 4.18%

	Q3 FY24	Q/Q Change
Total Assets	$96.6M	↓ 6.04%
Total Liabilities	$31.8M	↓ 11.49%

	FY18	Y/Y Change
Operating Cash Flow	$-30.9M	↑ 1.2%
Investing Cash Flow	$11.8M	↓ 215.56%
Financing Cash Flow	$5.8M	↓ 89.58%

	FY19	Y/Y Change
Operating Cash Flow	$-31.9M	↑ 3.45%
Investing Cash Flow	$17.0M	↑ 43.51%
Financing Cash Flow	$617.0K	↓ 89.31%

	FY20	Y/Y Change
Operating Cash Flow	$-19.8M	↓ 38.17%
Investing Cash Flow	$13.0M	↓ 23.11%
Financing Cash Flow	$29.9M	↑ 4740.36%

	FY21	Y/Y Change
Operating Cash Flow	$-23.6M	↑ 19.28%
Investing Cash Flow	$9.7M	↓ 25.26%
Financing Cash Flow	$36.9M	↑ 23.66%

	FY22	Y/Y Change
Operating Cash Flow	$1.1M	↓ 104.49%
Investing Cash Flow	$-46.2M	↓ 573.67%
Financing Cash Flow	$1.6M	↓ 95.58%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.3M	↓ 44.24%
Investing Cash Flow	$19.2M	↑ 24.2%
Financing Cash Flow	$5.6M	↑ 562700.0%

Lineage Cell Therapeutics Inc Technicals Summary

Sell

Neutral

Buy

Lineage Cell Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Lineage Cell Therapeutics Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lineage Cell Therapeutics Inc	-38.25%	-41.11%	-46.62%	-75.17%	-23.15%
Regeneron Pharmaceuticals, Inc.	-5.97%	-23.44%	-9.57%	20.91%	110.02%
Biontech Se	11.44%	18.44%	16.6%	-60.74%	309.79%
Alnylam Pharmaceuticals, Inc.	-7.77%	64.82%	42.06%	39.68%	108.61%
Vertex Pharmaceuticals Incorporated	-6.83%	-4.79%	29.94%	124.11%	109.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lineage Cell Therapeutics Inc	NA	NA	NA	-0.11	-0.35	-0.13	NA	0.36
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lineage Cell Therapeutics Inc	Buy	$125.9M	-23.15%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	110.02%	18.56	33.61%
Biontech Se	Buy	$28.5B	309.79%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	108.61%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	109.65%	32.84	-4.51%

About Lineage Cell Therapeutics Inc

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Organization	Lineage Cell Therapeutics Inc
Employees	68
CEO	Mr. Brian M. Culley M.A., M.B.A.
Industry	Health Technology

Management People of Lineage Cell Therapeutics Inc

Name	Title
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary
Ms. Ioana C. Hone	Director of Investor Relations
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant
Mr. William Annett MBA	President & CEO of OncoCyte Corporation
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences
Ms. Alexandra Hernandez	Senior Director of Finance & Controller
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control

Important FAQs about investing in Lineage Cell Therapeutics Inc from India :

What is Lineage Cell Therapeutics Inc share price today?

Lineage Cell Therapeutics Inc (LCTX) share price today is $0.57.

Can Indians buy Lineage Cell Therapeutics Inc shares?

Yes, Indians can invest in the Lineage Cell Therapeutics Inc (LCTX) from India.

With INDmoney, you can buy Lineage Cell Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Lineage Cell Therapeutics Inc at zero transaction cost.

How can I buy Lineage Cell Therapeutics Inc shares from India?

It is very easy to buy Lineage Cell Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Lineage Cell Therapeutics Inc be purchased?

Yes, you can buy fractional shares of Lineage Cell Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Lineage Cell Therapeutics Inc stocks?

To start investing in Lineage Cell Therapeutics Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.